论文部分内容阅读
目的探讨单纯子宫腺肌病病灶切除术后联合促性腺激素释放激素激动剂治疗子宫腺肌病的临床疗效。方法选取本院2012年7月~2013年8月收治的80例子宫腺肌病患者为研究对象,将其随机分成A组与B组,A组35例患者给予单纯子宫腺肌病病灶切除术进行治疗,B组45例患者在子宫腺肌病病灶切除术后联合促性腺激素释放激素激动剂进行治疗,观察两组临床疗效。结果治疗3个月后,B组患者痛经VAS评分、月经量、复发率均明显较A组改善效果好,差异均具有统计学意义(P<0.05)。结论单纯子宫腺肌病病灶切除术后联合促性腺激素释放激素激动剂治疗子宫腺肌病的临床疗效显著,能有效提高患者预后质量,值得临床推广应用。
Objective To investigate the clinical efficacy of combined gonadotropin-releasing hormone agonist in the treatment of adenomyosis after focal resection of adenomyosis. Methods Eighty patients with adenomyosis admitted from July 2012 to August 2013 in our hospital were selected and randomly divided into group A and group B. A group of 35 patients were given adenomyosis resection For treatment, 45 patients in group B were treated with gonadotropin-releasing hormone agonist after focal resection of adenomyosis and the clinical curative effect was observed. Results After 3 months of treatment, the VAS score, menstrual flow rate and recurrence rate in group B were significantly better than those in group A, and the differences were statistically significant (P <0.05). Conclusions Adenomyosis alone after resection combined with gonadotropin-releasing hormone agonist in the treatment of adenomyosis clinical efficacy was significant, can effectively improve the quality of patients with prognosis, it is worth promoting the clinical application.